3-(dimethylaminocarbonylthio)pyridine | 13511-89-2

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 3-(dimethylaminocarbonylthio)pyridine
• 英文别名: 3-(N,N-dimethylaminocarbonyl)mercaptopyridine；S-(pyridin-3-yl)-dimethylcarbamothioate；dimethyl-thiocarbamic acid S-pyridin-3-yl ester；dimethyl-thiocarbamic acid S-[3]pyridyl ester；Dimethyl-thiocarbamidsaeure-S-[3]pyridylester；S-pyridin-3-yl-dimethylcarbamothioate；N,N-dimethyl-1-(pyridin-3-ylsulfanyl)formamide；S-pyridin-3-yl N,N-dimethylcarbamothioate
• CAS: 13511-89-2
• 化学式: C₈H₁₀N₂OS
• mdl: MFCD16547671
• 分子量: 182.246
• InChiKey: LJUACVJOFBXXSG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  58.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(dimethylaminocarbonylthio)pyridine 在 甲醇 、 sodium 作用下， 反应 2.0h， 生成 吡啶-3-硫醇
  参考文献：
  名称：

  [EN] CARBACEPHEM ß-LACTAM ANTIBIOTICS
  [FR] ANTIBIOTIQUES BÊTA-LACTAMES À CARBACÉPHÈME

  摘要：

  Carbacephem β-内酰胺抗生素具有以下化学结构（I）和（II），包括立体异构体、药用可接受的盐、酯和前药，其中Ar2、R1、R2和R3如本文所定义。这些化合物可用于治疗细菌感染，特别是由耐甲氧西林葡萄球菌属引起的感染。

  公开号：

  WO2009055696A1
• 作为产物：
  描述：

  3-溴吡啶 在 1,2-丙二醇 、 铜 、 potassium hydrosulfide 、 三乙胺 、 苯 作用下， 生成 3-(dimethylaminocarbonylthio)pyridine
  参考文献：
  名称：

  Some Derivatives of 3-Pyridol with Parasympathomimetic Properties¹

  摘要：

  DOI：

  10.1021/ja01147a099

文献信息

• Inhibitors of protein isoprenyl transferases
  申请人：University of Pittsburgh

  公开号：US20020193596A1

  公开（公告）日：2002-12-19

  Compounds having the formula 1 or a pharmaceutically acceptable salt thereof wherein R 1 is (a) hydrogen, (b) loweralkyl, (c) alkenyl, (d) alkoxy, (e) thioalkoxy, (f) halo, (g) haloalkyl, (h) aryl-L 2 —, and (i) heterocyclic-L 2 —; R 2 is selected from (a) 2 (b) —C(O)NH—CH(R 14 )—C(O)OR 15 , (c) 3 (d) —C(O)NH—CH(R 14 )—C(O)NHSO 2 R 16 (e) —C(O)NH—CH(R 14 )-tetrazolyl, (f) —C(O)NH-heterocyclic, and (g) —C(O)NH—CH(R 14 )—C(O)NR 17 R 18 ; R 3 is heterocyclic, aryl, substituted or unsubstituted cycloalkyl; R 4 is hydrogen, lower alkyl, haloalkyl, halogen, aryl, arylakyl, heterocyclic, or (heterocyclic)alkyl; L 1 is absent or is selected from (a) —L 4 —N(R 5 )—L 5 —, (b) —L 4 —O—L 5 —, (c) —L 4 —S(O) n —L 5 — (d) —L 4 -L 6 —C(W)—N(R 5 )—L 5 —, (e) —L 4 -L 6 —S(O) m —N(R 5 )—L 5 —, (f) —L 4 —N(R 5 )—C(W)—L 7 -L 5 —, (g) —L 4 —N(R 5 )—S(O) p —L 7 —L 5 —, (h) optionally substituted alkylene, (i) optionally substituted alkenylene, and (j) optionally substituted alkynylene are inhibitors of protein isoprenyl transferases. Also disclosed are protein isoprenyl transferase inhibiting compositions and a method of inhibiting protein isoprenyl transferases.

  具有以下公式的化合物或其药学上可接受的盐，其中R1为(a)氢，(b)较低的烷基，(c)烯基，(d)烷氧基，(e)硫代烷氧基，(f)卤素，(g)卤代烷基，(h)芳基-L2—，以及(i)杂环-L2—；R2从(a)中选择，(b) -C(O)NH-CH(R14)-C(O)OR15，(c)中选择，(d) -C(O)NH-CH(R14)-C(O)NHSO2R16，(e) -C(O)NH-CH(R14)-四唑基，(f) -C(O)NH-杂环，以及(g) -C(O)NH-CH(R14)-C(O)NR17R18；R3为杂环，芳基，取代或未取代的环烷基；R4为氢，较低烷基，卤代烷基，卤素，芳基，芳基烷基，杂环基，或(杂环)烷基；L1为空缺或从(a) -L4-N(R5)-L5-，(b) -L4-O-L5-，(c) -L4-S(O)n-L5-，(d) -L4-L6-C(W)-N(R5)-L5-，(e) -L4-L6-S(O)m-N(R5)-L5-，(f) -L4-N(R5)-C(W)-L7-L5-，(g) -L4-N(R5)-S(O)p-L7-L5-，(h)可选择取代的烷基，(i)可选择取代的烯基，以及(j)可选择取代的炔基是蛋白异戊二烯转移酶的抑制剂。还公开了蛋白异戊二烯转移酶抑制组合物和抑制蛋白异戊二烯转移酶的方法。
• [EN] ATG7 INHIBITORS AND THE USES THEREOF<br/>[FR] INHIBITEURS D'ATG7 ET LEURS UTILISATIONS
  申请人：MILLENNIUM PHARM INC

  公开号：WO2018089786A1

  公开（公告）日：2018-05-17

  Disclosed are chemical entities which are compounds of formula (I) : or a pharmaceutically acceptable salt thereof, wherein R1, R2, and Ra have the values described herein. Chemical entities according to the disclosure can be useful as inhibitors of ATG7. Further provided are pharmaceutical compositions comprising a chemical entity of the disclosure and methods of using the compositions in the treatment of cancer.

  本公开涉及化学实体，其为以下式（I）的化合物：或其药学上可接受的盐，其中R1、R2和Ra具有此处描述的值。根据本公开的化学实体可以用作ATG7的抑制剂。还提供了包括本公开的化学实体的药物组合物以及使用这些组合物治疗癌症的方法。
• Discovery of Lipophilic Bisphosphonates That Target Bacterial Cell Wall and Quinone Biosynthesis
  作者：Satish R. Malwal、Lu Chen、Hunter Hicks、Fiona Qu、Weidong Liu、Alli Shillo、Wen Xuan Law、Jianan Zhang、Neal Chandnani、Xu Han、Yingying Zheng、Chun-Chi Chen、Rey-Ting Guo、Ahmed AbdelKhalek、Mohamed N. Seleem、Eric Oldfield

  DOI：10.1021/acs.jmedchem.8b01878

  日期：2019.3.14

  embryonic kidney cell line. Targeting of isoprenoid biosynthesis is involved with 74 having IC50 values of ∼100 nM against heptaprenyl diphosphate synthase and 200 nM against farnesyl diphosphate synthase. B. subtilis growth inhibition was rescued by addition of farnesyl diphosphate, menaquinone-4 (MK-4), or undecaprenyl phosphate (UP), and the combination of MK-4 and UP resulted in a 25× increase in ED50,

  我们报告说烷基取代的双膦酸盐具有抗炭疽芽孢杆菌（0.40μg/ mL），耻垢分枝杆菌（1.4μg/ mL），枯草芽孢杆菌（1.0μg/ mL）和金黄色葡萄球菌（13μg/ mL）的活性。在许多情况下，没有血清结合作用，也没有针对人类胚胎肾细胞系的低活性。异戊二烯生物合成的目标涉及74个抗庚二烯基二磷酸合酶的IC50值为〜100 nM，抗法呢基二磷酸合酶的IC50值为〜200 nM。枯草芽孢杆菌的生长抑制可通过添加法呢基二磷酸酯，甲萘醌4（MK-4）或十一碳烯基磷酸酯（UP）来挽救，MK-4和UP的组合导致ED50升高25倍，表明靶向醌和细胞壁的生物合成。艰难梭菌被74抑制，并且由于该生物体不合成醌，因此细胞壁生物合成可能成为目标。我们还解决了与八烯丙基二磷酸和/或十一碳烯基二磷酸合酶结合的抑制剂的三种X射线结构。
• Pyridine derivatives, their production and use
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US05246948A1

  公开（公告）日：1993-09-21

  There is disclosed a pharmaceutical composition for providing antiinflammatory, antipyretic, analgesic, antiallergic, immunosuppressing or immunomodulating activity which comprises a pyridine derivative of the formula (I): ##STR1## wherein R is an optionally substituted pyridine ring, X is a oxygen atom or --S(O)n--, wherein n is 0, 1 or 2, A is a bivalent C.sub.1-15 hydrocarbon residue whose branched moiety may have a substituent, Y is an oxygen or sulfur atom, R.sub.3 is a hydrogen atom or an optionally substituted hydrocarbon residue, R.sub.4 is an optionally substituted hydrocarbon residue or an optionally substituted monocyclic or bicyclic heterocyclic group, R.sub.3 and R.sub.4 may be joined together with the carbamoyl group or the thiocarbamoyl group to which they are attached to form an optionally substituted heterocyclic group, or R.sub.3 or R.sub.4 may be independently attached to A to form a ring, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier or diluent.

  揭示了一种用于提供抗炎、退烧、镇痛、抗过敏、免疫抑制或免疫调节活性的药物组合物，其包括下式的吡啶衍生物（I）：其中R是一个可选取代的吡啶环，X是一个氧原子或--S（O）n--，其中n为0、1或2，A是一种二价的C.sub.1-15烃残基，其支链可能有取代基，Y是氧或硫原子，R.sub.3是氢原子或一个可选取代的烃残基，R.sub.4是一个可选取代的烃残基或一个可选取代的单环或双环杂环基，R.sub.3和R.sub.4可以与它们附着的氨甲酰基或硫氨甲酰基结合在一起形成一个可选取代的杂环基，或者R.sub.3或R.sub.4可以独立地连接到A上形成一个环，或其药学上可接受的盐或溶剂，以及药学上可接受的载体或稀释剂。
• [EN] GOLD (I)-PHOSPHINE COMPOUNDS AS ANTI-BACTERIAL AGENTS<br/>[FR] COMPOSÉS OR (I)-PHOSPHINE UTILISÉS COMME AGENTS ANTI-BACTÉRIENS
  申请人：AUSPHERIX LTD

  公开号：WO2015181551A1

  公开（公告）日：2015-12-03

  A compound of formula (I): for use in the prevention or treatment of a bacterial infection wherein: A is either S or Se; RA is selected from: wherein: each of Y1, Y2, Y3, Y4 and Y9 is independently selected from CH or N, wherein at least three of Y1, Y2, Y3, Y4 and Y9 is CH; V is selected from O, CH-OR01, N-CO2-RC2 or N-RN2; one of Y5, Y6, Y7 and Y8 is selected from CH and N, and the others are CH; X is selected from NH, S or O; RC1 is selected from O-RO2 or NHRN1; RO1 is selected from H and C1-3 unbranched alkyl; RO2 is C1-3 unbranched alkyl; RN1 is selected from H and C1-3 unbranched alkyl; RN2 is C1-3 unbranched alkyl; RC2 is either C1-3 unbranched alkyl or C3-4 branched alkyl; RC3 is selected from C1-3 unbranched alkyl and C2H4CO2H; RC4 is either H or Me; RC5 is either H or Me; RC6 represents one or two optional methyl substituents; and n is an integer from 2 to 8.

  化合物公式（I）的用途是用于预防或治疗细菌感染，其中：A是S或Se; RA选自：其中：Y1、Y2、Y3、Y4和Y9中的每一个都是独立选择的CH或N，其中至少三个是CH; V选自O、CH-OR01、N-CO2-RC2或N-RN2; Y5、Y6、Y7和Y8中的一个选自CH和N，其他的是CH; X选自NH、S或O; RC1选自O-RO2或NHRN1; RO1选自H和C1-3直链烷基; RO2是C1-3直链烷基; RN1选自H和C1-3直链烷基; RN2是C1-3直链烷基; RC2是C1-3直链烷基或C3-4支链烷基; RC3选自C1-3直链烷基和C2H4CO2H; RC4是H或Me; RC5是H或Me; RC6代表一个或两个可选的甲基取代基; n是2到8的整数。